Yixintang Pharmaceutical Group Co., Ltd.
Symboli: 002727.SZ
SHZ
18.75
CNYMarkkinahinta tänään
23.9311
P/E-suhde
0.6980
PEG-suhde
11.17B
MRK Cap
- 0.02%
DIV Tuotto
Yixintang Pharmaceutical Group Co., Ltd. (002727-SZ) Tilinpäätöstiedotteet
Tase
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 3895.3 | 3520 | 2532.4 | |||||||||||||||
balance-sheet.row.short-term-investments | 0 | 219.7 | 8.4 | 297.3 | |||||||||||||||
balance-sheet.row.net-receivables | 0 | 1991.7 | 2411 | 1777.5 | |||||||||||||||
balance-sheet.row.inventory | 0 | 3852.6 | 3387.4 | 3317 | |||||||||||||||
balance-sheet.row.other-current-assets | 0 | 153.3 | 139.2 | 65.5 | |||||||||||||||
balance-sheet.row.total-current-assets | 0 | 9892.9 | 9457.6 | 7692.4 | |||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 3995.6 | 3993.5 | 4080 | |||||||||||||||
balance-sheet.row.goodwill | 0 | 1649.6 | 1397.2 | 1380 | |||||||||||||||
balance-sheet.row.intangible-assets | 0 | 184.1 | 165.7 | 122.9 | |||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 1833.7 | 1562.9 | 1502.8 | |||||||||||||||
balance-sheet.row.long-term-investments | 0 | 165.3 | 131.4 | -190.1 | |||||||||||||||
balance-sheet.row.tax-assets | 0 | 88.9 | 94.1 | 58.5 | |||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 670.8 | 939.5 | 1193.8 | |||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 6754.5 | 6721.5 | 6645 | |||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-assets | 0 | 16647.4 | 16179.1 | 14337.3 | |||||||||||||||
balance-sheet.row.account-payables | 0 | 2560.2 | 4328.8 | 3805.9 | |||||||||||||||
balance-sheet.row.short-term-debt | 0 | 3333.9 | 1335.5 | 1143.9 | |||||||||||||||
balance-sheet.row.tax-payables | 0 | 81.4 | 250.4 | 164.1 | |||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 1552.2 | 1758.5 | 1764.1 | |||||||||||||||
Deferred Revenue Non Current | 0 | 1.2 | 12.2 | 13.3 | |||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||
balance-sheet.row.other-current-liab | 0 | 1191.9 | 1055.8 | 12.7 | |||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 1557.3 | 1774.7 | 1781 | |||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 1552.2 | 1756.7 | 1729 | |||||||||||||||
balance-sheet.row.total-liab | 0 | 8757.1 | 8651.5 | 7664.8 | |||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.common-stock | 0 | 596 | 596 | 596.2 | |||||||||||||||
balance-sheet.row.retained-earnings | 0 | 4646.4 | 4335.4 | 3504.2 | |||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 377.8 | 424.9 | 405.6 | |||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 2125.8 | 2069.8 | 2071.7 | |||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 7746 | 7426.1 | 6577.7 | |||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 16647.4 | 16179.1 | 14337.3 | |||||||||||||||
balance-sheet.row.minority-interest | 0 | 131 | 101.4 | 94.8 | |||||||||||||||
balance-sheet.row.total-equity | 0 | 7877 | 7527.6 | 6672.5 | |||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||||
Total Investments | 0 | 385 | 139.8 | 107.2 | |||||||||||||||
balance-sheet.row.total-debt | 0 | 4886.1 | 3094 | 2908 | |||||||||||||||
balance-sheet.row.net-debt | 0 | 1210.5 | -417.6 | 672.9 |
Kassavirtalaskelma
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 549.4 | 1013 | 917.2 | |||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 1000.6 | 1087.8 | |||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | -35.1 | -27.3 | |||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 14.2 | 40.4 | |||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 0 | -9.7 | -603.9 | |||||||||||||||
cash-flows.row.account-receivables | 0 | 0 | -765.8 | -739.7 | |||||||||||||||
cash-flows.row.inventory | 0 | 0 | -234.9 | -1236.8 | |||||||||||||||
cash-flows.row.account-payables | 0 | 0 | 1026.1 | 1399.9 | |||||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | -35.1 | -27.3 | |||||||||||||||
cash-flows.row.other-non-cash-items | 0 | -549.4 | 514.1 | 377.5 | |||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | -349 | -391.6 | |||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | -4.7 | -65.1 | |||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | -980.5 | -1976.5 | |||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 1207.2 | 2901.8 | |||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | -94.7 | -336.9 | |||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 0 | -221.7 | 131.7 | |||||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -207.9 | -137.1 | |||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 2 | 0.1 | |||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | -2 | -0.1 | |||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | -191.6 | -180.9 | |||||||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | -678.6 | -986.8 | |||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 0 | -1078.2 | -1304.8 | |||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0.3 | -0.1 | |||||||||||||||
cash-flows.row.net-change-in-cash | 0 | 0 | 1197.5 | 618.5 | |||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 2859.5 | 2859.5 | 1661.9 | |||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 2859.5 | 1661.9 | 1043.5 | |||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 0 | 2497.1 | 1791.7 | |||||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | -349 | -391.6 | |||||||||||||||
cash-flows.row.free-cash-flow | 0 | 0 | 2148.1 | 1400 |
Tuloslaskelmarivi
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 17301.4 | 17431.6 | 14587.4 | |||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 11750.3 | 11322.3 | 9196.5 | |||||||||||||||
income-statement-row.row.gross-profit | 0 | 5551 | 6109.3 | 5390.9 | |||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-expenses | 0 | -106.6 | 349.1 | 320.6 | |||||||||||||||
income-statement-row.row.operating-expenses | 0 | 4717.5 | 4496.8 | 4091.3 | |||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 16467.8 | 15819.1 | 13287.8 | |||||||||||||||
income-statement-row.row.interest-income | 0 | -77.6 | 53.4 | 39.2 | |||||||||||||||
income-statement-row.row.interest-expense | 0 | 135.3 | 147.1 | 136.2 | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -123.6 | -426.9 | 28.6 | |||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | -106.6 | 349.1 | 320.6 | |||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -123.6 | -426.9 | 28.6 | |||||||||||||||
income-statement-row.row.interest-expense | 0 | 135.3 | 147.1 | 136.2 | |||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 1332.4 | 1000.6 | 1397.7 | |||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.operating-income | 0 | 833.5 | 1661.9 | 1067.9 | |||||||||||||||
income-statement-row.row.income-before-tax | 0 | 709.9 | 1235 | 1096.5 | |||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 142.2 | 222 | 179.3 | |||||||||||||||
income-statement-row.row.net-income | 0 | 549.4 | 1010 | 921.6 |
Usein kysytty kysymys
Mikä on Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) taseen loppusumma?
Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) kokonaisvarat ovat 16647375283.000.
Mikä on yrityksen vuotuinen liikevaihto?
Vuotuinen liikevaihto on N/A.
Mikä on yrityksen voittomarginaali?
Yrityksen voittomarginaali on 0.318.
Mikä on yrityksen vapaa kassavirta?
Vapaa kassavirta on 3.367.
Mikä on yrityksen nettovoittomarginaali?
Nettovoittomarginaali on 0.031.
Mikä on yrityksen kokonaistulot?
Kokonaisliikevaihto on 0.045.
Mikä on Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) nettovoitto (nettotulos)?
Nettovoitto (nettotulos) on 549441525.000.
Mikä on yrityksen kokonaisvelka?
Kokonaisvelka on 4886107552.000.
Mikä on yrityksen toimintakulujen määrä?
Toimintakulut ovat 4717493463.000.
Mikä on yrityksen kassan määrä?
Yrityksen kassavarat ovat 0.000.